** Shares of Regenxbio RGNX.O jump 5.9% to $11.10

** The drug developer will receive $100 million milestone payment from partner AbbVie ABBV.N after dosing first patient in a mid-to-late-stage study of surabgene lomparvovec, its experimental one-time gene therapy for diabetic retinopathy

** The diabetes-related eye disease is a leading cause of vision loss among working-age adults

** The study is expected to enroll about 135 patients in the U.S.; the main goal is improvement in disease severity after one year - RGNX

** Plans to present longer-term data from its diabetic retinopathy and wet AMD programs at a retina specialists meeting in July

** Including session's move, RGNX down 22.6% YTD